261280558 Stock Overview A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
PharmaEssentia Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for PharmaEssentia Historical stock prices Current Share Price NT$20.40 52 Week High NT$0 52 Week Low NT$0 Beta 0.56 1 Month Change 9.09% 3 Month Change 6.81% 1 Year Change 102.66% 3 Year Change n/a 5 Year Change n/a Change since IPO 47.87%
Recent News & Updates
PharmaEssentia Corp Announces China NMPA has Accepted the Phase III Clinical Trial Application of P1101 for Pre-fibrotic/Early PMF or Overt PMF at Low or Intermediate-1 Risk Jan 15
PharmaEssentia Corporation Announces Positive Topline Phase 3 Data from Surpass-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia Jan 07
PharmaEssentia Corporation Announces Positive Topline Results from Phase 3 Clinical Trial of P1101 for ET Jan 05
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors to TFDA Jan 03
Pharmaessentia Corporation Appoints Joseph R. Horvat as Global Chief Commercial Officer Dec 05
PharmaEssentia Corporation Announces Nine Data Presentations at ASH Annual Meeting Nov 26 See more updates
PharmaEssentia Corp Announces China NMPA has Accepted the Phase III Clinical Trial Application of P1101 for Pre-fibrotic/Early PMF or Overt PMF at Low or Intermediate-1 Risk Jan 15
PharmaEssentia Corporation Announces Positive Topline Phase 3 Data from Surpass-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia Jan 07
PharmaEssentia Corporation Announces Positive Topline Results from Phase 3 Clinical Trial of P1101 for ET Jan 05
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors to TFDA Jan 03
Pharmaessentia Corporation Appoints Joseph R. Horvat as Global Chief Commercial Officer Dec 05
PharmaEssentia Corporation Announces Nine Data Presentations at ASH Annual Meeting Nov 26
PharmaEssentia Corporation to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
PharmaEssentia Corporation Announces Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon Alfa-2b for Essential Thrombocythemia (ET) Oct 18
PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle Sep 07
PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 06
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors Jul 03
Pharmaessentia Corporation Announces Appointments to Board of Directors May 30 Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee
PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA May 23
PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024 May 08
PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA Apr 27
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia Apr 26 PharmaEssentia Corporation announced a financing transaction Apr 03
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA Mar 06
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration Mar 05
PharmaEssentia Corporation, Annual General Meeting, May 27, 2024 Feb 28
PharmaEssentia Corporation, Annual General Meeting, May 27, 2024 Feb 27
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA Jan 18
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia Oct 27
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China Sep 21
PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts Aug 09
PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV) Jul 01
PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong May 08 Shareholder Returns 261280558 LU Biotechs LU Market 7D -2.9% -0.9% 0.3% 1Y 102.7% 14.6% -0.9%
See full shareholder returns
Return vs Market: 261280558 exceeded the Luxembourg Market which returned -4% over the past year.
Price Volatility Is 261280558's price volatile compared to industry and market? 261280558 volatility 261280558 Average Weekly Movement 6.4% Biotechs Industry Average Movement 7.9% Market Average Movement 5.1% 10% most volatile stocks in LU Market 6.7% 10% least volatile stocks in LU Market 3.2%
Stable Share Price: 261280558's share price has been volatile over the past 3 months compared to the Luxembourg market.
Volatility Over Time: 261280558's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Luxembourg stocks.
About the Company PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
Show more PharmaEssentia Corporation Fundamentals Summary How do PharmaEssentia's earnings and revenue compare to its market cap? 261280558 fundamental statistics Market cap US$6.78b Earnings (TTM ) US$56.11m Revenue (TTM ) US$252.94m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 261280558 income statement (TTM ) Revenue NT$8.32b Cost of Revenue NT$1.07b Gross Profit NT$7.25b Other Expenses NT$5.40b Earnings NT$1.85b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 5.54 Gross Margin 87.10% Net Profit Margin 22.19% Debt/Equity Ratio 0.3%
How did 261280558 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/04 00:21 End of Day Share Price 2025/02/04 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources PharmaEssentia Corporation is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Capital Securities Corporation Jianzheng Wu Capital Securities Corporation Wangbin Zhou Citigroup Inc
Show 6 more analysts 